Glaucomas: Neovascular glaucoma

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Topical and oral medical therapies are the initial treatment of choice to lower intraocular pressure (IOP) and limit vision loss and pain secondary to neovascular glaucoma (NVG). Therapies aimed at decreasing aqueous production (beta-blockers, topical and systemic carbonic anhydrase inhibitors, and alpha adrenergics) have the soundest rationale for use in NVG. No study is available in the literature comparing effectiveness of these various medications in NVG, and they are often required in combination. If the IOP is markedly elevated, it would not be inappropriate to commence simultaneously with an alpha-agonist, topical nonselective beta blocker, and topical carbonic anhydrase inhibitor.

Original languageEnglish (US)
Title of host publicationPearls of Glaucoma Management
PublisherSpringer Berlin Heidelberg
Pages379-387
Number of pages9
ISBN (Print)9783540682387
DOIs
StatePublished - Dec 1 2010

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wenick, A. S., & Robin, A. L. (2010). Glaucomas: Neovascular glaucoma. In Pearls of Glaucoma Management (pp. 379-387). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-68240-0_49